archive-com.com » COM » N » NEXTECHINVEST.COM

Total: 35

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Home | Nextechinvest
    Immunotherapeutics to create highly durable cancer treatments Kura Oncology IPO Small molecules that target cancer signaling pathways MacroGenics Full Exit Antibodies for cancer immunotherapy Molecular MD Market Cancer genotyping for targeted cancer therapies Palyon Liquidated Implantable drug pumps for palliative care and diabetes Peloton Clinical Phase I Small molecule programs with a distinct target and mechanism of action Sunesis Partial exit Small molecules for acute myeloid leukemia Telormedix Sale of shares Targeted immunity in cancer and other diseases TetraLogic Full Exit Small molecule Smac mimetics for treatment of cancers TRACON IPO Antibodies targeting endoglin in cancer angiogenesis Corporate Presentation Get it now 21 04 2016 TRACON announces clinical data presentations 17 04 2016 Jounce Therapeutics presents data highlighting Corporate Presentation Get it now Portfolio Companies Game Changing Cancer Companies Agensys Acquired Fully human antibody drug conjugates for pancreatic cancer Blueprint IPO Highly selective kinase inhibitors for genomically defined cancer subsets Ganymed Acquired Ideal monoclonal antibodies for cancer treatment ImaginAB Clinical Phase II Antibody fragments for imaging of cancer Jounce Therapeutics Preclinical Immunotherapeutics to create highly durable cancer treatments Kura Oncology IPO Small molecules that target cancer signaling pathways MacroGenics Full Exit Antibodies for cancer immunotherapy Molecular MD Market Cancer genotyping for targeted cancer therapies Palyon Liquidated Implantable drug pumps for palliative care and diabetes Peloton Clinical Phase I Small molecule programs with a distinct target and mechanism of action Sunesis Partial exit Small molecules for acute myeloid leukemia Telormedix Sale of shares Targeted immunity in cancer and other diseases TetraLogic Full Exit Small molecule Smac mimetics for treatment of cancers TRACON IPO Antibodies targeting endoglin in cancer angiogenesis Agensys Acquired Fully human antibody drug conjugates for pancreatic cancer Blueprint IPO Highly selective kinase inhibitors for genomically defined cancer subsets Ganymed Acquired Ideal monoclonal antibodies for cancer treatment ImaginAB Clinical Phase

    Original URL path: http://www.nextechinvest.com/ (2016-04-26)
    Open archived version from archive


  • About | Nextech Invest | Nextechinvest
    active late stage oncology fund Nextech III Oncology building on the success of its predecessor fund followed in 2010 and most recently Nextech IV Oncology which had its final closing in early 2016 Nextech Invest Focus We deploy our expertise in oncology to invest equity in cancer companies with leadership teams active in the fields of therapy medical technology and diagnostics supported by a coherent and eminent group of eight

    Original URL path: http://www.nextechinvest.com/en/about.html (2016-04-26)
    Open archived version from archive

  • About | Oncology Expertise | Nextechinvest
    available As society ages incidence of cancer has risen to become a leading cause of death worldwide It is estimated that more than 14 1 million new cases of cancer arise each year The demand for more effective and better tolerated cancer drugs is high resulting in the biggest and fastest growing market in healthcare Nextech Invest has built a strong team of experienced investment professionals and world class scientific advisors to invest in top cancer companies worldwide The management team and the 8 member Scientific Board evaluate companies together based on scientific quality management strength investor syndicate and competitive landscape What is oncology Oncology is the medical and scientific study of cancer Cancer is a lethal disease of abnormal cells that grow uncontrollably and spread throughout the body There are over 200 different types of cancer that can develop in any organ in the body Sitemap Sitemap Home About Nextech Invest Oncology Expertise Investment Strategy Selection Process Investment Criteria Team Portfolio Investors News Contact Nextech Invest Ltd Turnerstrasse 26 8006 Zurich Switzerland P 41 0 44 366 66 11 F 41 0 44 366 66 10 Newsletter Registration Please fill in the subscription form completely If you wish to

    Original URL path: http://www.nextechinvest.com/en/about/oncology-expertise.html (2016-04-26)
    Open archived version from archive

  • About | Investment Strategy | Nextechinvest
    has the potential to give a meaningful impact for cancer patients including orphan indications What are clinical trials Clinical trials are designed to test the safety and efficacy of a new drug After a drug has been through preclinical testing in laboratory experiments and animal models it undergoes three rigorous phases of human clinical trials safety efficacy and superiority The trial data are used for balancing effective dosing and side

    Original URL path: http://www.nextechinvest.com/en/about/investment-strategy.html (2016-04-26)
    Open archived version from archive

  • About | Selection Process | Nextechinvest
    in 14 companies since 2007 and look forward to continue as many exciting opportunities appear as a result of the enormous efforts by the global scientific community Traditional cancer treatments Traditional treatments include chemotherapy radiation and surgery with the objective to eradicate cancer cells while sparing healthy cells Most current therapies come with undesirable side effects and often lack significant efficacy With ongoing research treatments are becoming increasingly effective and

    Original URL path: http://www.nextechinvest.com/en/about/selection-process.html (2016-04-26)
    Open archived version from archive

  • About | Investment Criteria | Nextechinvest
    trade sale the route independent from financial market conditions Emerging cancer treatments Emerging cancer treatments are continuously improving efficacy and side effects for the benefit of patients Antibody therapies and targeted inhibitors selectively kill cancer cells while sparing healthy cells Immunotherapies can train the patients own failing immune system to attack conquer cancer cells Sitemap Sitemap Home About Nextech Invest Oncology Expertise Investment Strategy Selection Process Investment Criteria Team Portfolio

    Original URL path: http://www.nextechinvest.com/en/about/investment-criteria.html (2016-04-26)
    Open archived version from archive

  • Team | Nextechinvest
    School Sir Bruce A J Ponder Head Department of Oncology University of Cambridge Charles L Sawyers Chair Human Oncology Program MSKCC Paul Workman Chief Executive and President Institute of Cancer Research Kai Wucherpfennig Chair Department of Cancer Immunology and Virology DFCI ASCO Annual Meeting 03 06 07 06 2016 Chicago USA 21 04 2016 TRACON announces clinical data presentations 17 04 2016 Jounce Therapeutics presents data highlighting Sitemap Sitemap Home

    Original URL path: http://www.nextechinvest.com/en/team.html (2016-04-26)
    Open archived version from archive

  • Portfolio | Nextechinvest
    US Holding Inc the US subsidiary of Astellas Pharma Inc acquired Agensys For more information contact Alfred Scheidegger Astellas Pharma US Inc Illinois USA Phone 1 847 317 54 05 www astellas us Blueprint Medicines is a patient driven oncology company developing highly selective kinase inhibitors for genomically defined cancer subsets Led by a management team and advisors with world renowned expertise in cancer genomics drug discovery and clinical oncology Blueprint has developed a platform that combines genomics with a novel library of kinase inhibitors enabling Blueprint to rapidly develop potent highly selective compounds against clear genomic driver targets Blueprint Medicines was founded in 2011 and was initially financed by Third Rock Ventures and Fidelity Bioscience with corporate headquarters in Cambridge Massachusetts For more information contact Thilo Schroeder Blueprint Medicines Inc 215 First Street Cambridge MA 02142 USA Phone 1 617 374 75 80 www blueprintmedicines com Ganymed Pharmaceuticals AG is a leading biopharmaceutical company offering smart antibody therapies for ideal targets in solid cancers The company s discovery engine is one of the industry s most powerful integrated approaches to building an antibody cancer pipeline A multi centre first in man clinical phase I study with Ganymed s Claudiximab antibody in patients with metastatic adenocarcinoma of the stomach and the lower esophagus has been successfully concluded The company has five further antibody projects in non clinical development in solid cancers with high unmet medical need including melanomas prostate cancers lung cancers breast cancers colorectal cancers and cancers of the head and neck Founded in 2001 as a spin off of the Universities of Mainz and Zurich the company is located in Mainz Germany and has 70 employees In August 2008 the majority of the company shares were sold to ATS For more information contact Alfred Scheidegger Ganymed Pharmaceuticals AG Freiligrathstrasse 12 55131 Mainz Germany Phone 49 6131 144 01 00 info ganymed pharmaceuticals com www ganymed pharmaceuticals de Kura Oncology is a clinical stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers Kura Oncology brings together a proven team of drug developers and biotech entrepreneurs Kura Oncology s diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment Kura Oncology s approach to drug development is focused on rapidly translating novel science into life saving medicines For more information contact Thilo Schroeder Kura Oncology Corporate Headquarters 11119 North Torrey Pines Road Suite 125 La Jolla CA 92037 www kuraoncology com MacroGenics Full Exit Antibodies for cancer immunotherapy Rockville MD USA Palyon Liquidated Implantable drug pumps for palliative care and diabetes Santa Clarita CA USA Sunesis Partial exit Small molecules for acute myeloid leukemia South San Francisco CA USA Telormedix Sale of shares Targeted immunity in cancer and other diseases Bioggio Switzerland Since its founding in 2000 MacroGenics has focused on applying its world class

    Original URL path: http://www.nextechinvest.com/en/portfolio.html (2016-04-26)
    Open archived version from archive



  •